Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
AC Immune SA
AC Immune SA
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Manufacturing
AC Immune strengthens management, appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
Retiring CSO Dr. Marie Kosco-Vilbois will remain as consultant to ensure smooth handover
Pharmaceutical
AC Immune SA appoints Dr Marie Kosco-Vilbois
Neurodegenerative Disease company has new Chief Scientific Officer
Pharmaceutical
New strategic partnership focuses on Alzheimers
Swiss AC Immune and Chinese WuXi Biologics sign agreement
Research & Development
AC Immune and Lilly announce licence and collaboration agreement
Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerative diseases
Pharmaceutical
Landmark for AC Immune Alzheimer and Down Syndrome vaccines
The swiss clinical stage biopharmaceutical company has a broad pipeline focused on neurodegenerative diseases
Subscribe now